What is GreenMark Biomedical?
GreenMark Biomedical is at the forefront of developing advanced products utilizing proprietary small sub-micron particles derived from food-grade starch. These biodegradable particles serve as an ideal carrier system for medical and dental applications. The company's primary focus is on addressing dental caries, the world's most prevalent chronic disease, by creating non-invasive methods for early-stage identification, assessment, monitoring, and treatment. Their LumiCare Caries Detection Rinse, designed for dental professionals, employs fluorescently labeled starch particles that target subsurface carious lesions, illuminating them under a blue curing light for enhanced diagnostic capabilities.
How much funding has GreenMark Biomedical raised?
GreenMark Biomedical has raised a total of $3.5M across 3 funding rounds:
Angel/Seed
$1.2M
Grant
$1.5M
Unspecified
$830K
Angel/Seed (2019): $1.2M with participation from Western Michigan University’s BRCC, Red Cedar Ventures, BlueWater Angels, Invest Michigan, Invest Detroit Ventures, and The University of Michigan’s MINTS program
Grant (2019): $1.5M led by Small Business Development Center
Unspecified (2022): $830K supported by Red Cedar Ventures, BlueWater Angels, University of Michigan MINTS fund, and Michigan Rise funds
Key Investors in GreenMark Biomedical
Red Cedar Ventures
Red Cedar Ventures is a venture capital fund focused on growing Michigan State University-based startup companies and accelerating the commercialization of MSU technologies, providing pre-seed and growth-stage capital.
BlueWater Angels
BlueWater Angels is an angel investment group that provides backing to promising early-stage companies, contributing to their growth and market development.
Invest Michigan
Invest Michigan is recognized as Michigan's most active technology investor, providing capital to early-stage, high-tech companies located within the state.
What's next for GreenMark Biomedical?
The recent major strategic investment positions GreenMark Biomedical for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and expand commercialization efforts for its innovative caries detection and treatment technologies. The company's focus on a prevalent global health issue, coupled with its unique starch-based particle technology, suggests a strong potential for significant impact and future funding rounds as it moves towards broader market adoption.
See full GreenMark Biomedical company page
